Immune reactions in benign and malignant melanocytic lesions: Lessons for immunotherapy

Pigment Cell and Melanoma Research

Volumn 24, Issue 2, 2011, Pages 334-344

  Speeckaert, R ^a   van Geel, N ^a   Vermaelen, K V ^a   Lambert, J ^a   Van Gele, M ^a   Speeckaert, M M ^a   Brochez, L ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Halo nevus; Immunosurveillance; Melanocyte; Melanoma; Melanoma associated depigmentation; Meyerson's nevus; Regression

Indexed keywords

CD68 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CXCR3; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FAS LIGAND; GAMMA INTERFERON; GRANZYME B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; MELAN A; MELANIN; MELANIN CONCENTRATING HORMONE RECEPTOR 1; MELANOMA ANTIGEN; PERFORIN; STEROID; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR NECROSIS FACTOR ALPHA; VERY LATE ACTIVATION ANTIGEN 4;

ACANTHOSIS; B LYMPHOCYTE; BENIGN SKIN TUMOR; BLUE NEVUS; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DESTRUCTION; CLINICAL FEATURE; CONGENITAL NEVUS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DEPIGMENTATION; DERMATITIS; DERMIS; DISEASE ASSOCIATION; DISEASE COURSE; ECZEMA; ENDOTHELIUM CELL; EOSINOPHIL; EPIDERMIS HYPERPLASIA; ERYTHEMA; HALO NEVUS; HISTOPATHOLOGY; HUMAN; HYPOPIGMENTATION; INFLAMMATORY INFILTRATE; INVOLUTION; JUVENILE MELANOMA; KERATINOCYTE; LANGERHANS CELL; LEUKODERMA; LYMPH NODE METASTASIS; LYMPHOCYTE ACTIVATION; MAST CELL; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; MELANOMA ASSOCIATED DEPIGMENTATION; MELANOSIS; METASTASIS; MEYERSON'S NEVUS; NATURAL KILLER CELL; NEVUS CELL; NONHUMAN; PARAKERATOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN INDURATION; SKIN METASTASIS; SKIN ULCER; STROMA; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; VASCULARIZATION; VITILIGO; WHITE SPONGE NEVUS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MELANOCYTES; MELANOMA; NEVUS; SKIN NEOPLASMS;

EID: 79952590872     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2010.00799.x     Document Type: Review

References (81)

1. Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., Wunderlich, J.R., Dudley, M.E., White, D.E., and Rosenberg, S.A. (2009). Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537-1544.
2. Andreani, V., Richard, M.A., Blaise, D., Gouvernet, J., and Grob, J.J. (2002). Naevi in allogeneic bone marrow transplantation recipients: the effect of graft-versus-host disease on naevi. Br. J. Dermatol. 147, 433-441.
3. Andreola, G., Rivoltini, L., Castelli, C. et al. (2002). Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 195, 1303-1316.
4. Barnhill, R.L., Fitzpatrick, T.B., Fandrey, K., Kenet, R.O., Mihm, M.C. Jr, and Sober, A.J. (1995). Color Atlas and Synopsis of Pigmented Lesions. (New York: McGraw-Hill).
5. Baron, J., and Krol, A. (2005). Management of nevi in transplant patients. Dermatol. Ther. 18, 34-43.
6. Bayer-Garner, I.B., Ivan, D., Schwartz, M.R., and Tschen, J.A. (2004). The immunopathology of regression in benign lichenoid keratosis, keratoacanthoma and halo nevus. Clin. Med. Res. 2, 89-97.
7. Bernsen, M.R., Diepstra, J.H.S., van Mil, P., Punt, C.J.A., Figdor, C.G., van Muijen, G.N.P., Adema, G.J., and Ruiter, D.J. (2004). Presence and localization of T-cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells. J. Pathol. 202, 70-79.
8. Blessing, K., and McClaren, K.M. (1992). Histological regression in primary cutaneous melanoma recognition, prevalence and significance. Histopathology 20, 315-322.
9. Bories, N., Dalle, S., Debarbieux, S., Balme, B., Ronger-Savl, S., and Thomas, L. (2008). Dermoscopy of fully regressive cutaneous melanoma. Clin. Lab. Invest. 158, 1224-1229.
10. Bos, J.D., and Luiten, R.M. (2009). Skin immune system. Cancer Treat. Res. 146, 45-62.
11. Brandt, O., Christophers, E., and Fölster-Holst, R. (2005). Halo dermatitis followed by the development of vitiligo associated with Sutton's nevi. J. Am. Acad. Dermatol. 52, S101-S104.
12. Brochez, L., Boone, B., and Naeyaert, J.M. (2006). Hypomelanoses associated with melanocytic neoplasia. In The Pigmentary System: Physiology and Pathophysiology, J.J., Nordlund, R.E., Boissy, V.J., Hearing, R.A., King, W.S., Oetting, and J., Ortonne, eds. (Oxford, UK: Blackwell Publishing), pp. 705-724.
13. Chang, C., Campoli, M., Restifo, N.P., Wang, X., and Ferrone, S. (2005). Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J. Immunol. 174, 1462-1471.
14. Conrad, C., Meller, S., and Gilliet, M. (2009). Plasmacytoid dendritic cells in the skin: to sense or not to sense nucleic acids. Semin. Immunol. 21, 101-109.
15. Cook-Norris, R.H., Zic, J.A., and Boyd, A.S. (2008). Meyerson's naevus: a clinical and histopathological study of 11 cases. Australas. J. Dermatol. 49, 191-195.
16. Cui, Z., and Willingham, M.C. (2004). Halo naevus: a visible case of immunosurveillance in humans? Lancet Oncol. 5, 397-398.
17. Cunha, D., Pacheco, F.A., and Cardoso, J. (2009). Vitiligo: a good prognostic factor in melanoma? Dermatol. Online J. 15, 15.
18. Cusack, C., Warde, D., Lynch, W., McDermott, M., and Watson, R. (2009). Dramatic spontaneous regression of a medium-sized congenital melanocytic naevus. Clin. Exp. Dermatol. 34, e34-e36.
19. Denfeld, R.W., Dietrich, A., Wuttig, C., Tanczos, E., Weiss, J.M., Vanscheidt, W., Schöpf, E., and Simon, J.C. (1995). In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity. Int. J. Cancer 28, 259-265.
20. Dranoff, G. (2009). Targets of protective tumor immunity. Ann. N. Y. Acad. Sci. 1174, 74-80.
21. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., and Schreiber, R.D. (2002). Cancer immunoediting from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998.
22. Everson, T.C., and Cole, W.H. (1966). Spontaneous Regression of Cancer. (Philadelphia: W.B. Saunders), pp. 164-220.
23. Feal-Cortizas, C., Vargas-Diez, E., Buezo, G.F., and Aragües, M. (1997). Meyerson's nevus immunohistochemical finding in two cases. Australas. J. Dermatol. 38(S2), 222.
24. Fernández Herrera, J.M., Aragüez Montañés, M., Fraga Fernández, J., and Diez, G. (1988). Halo eczema in melanocytic nevi. Acta Derm. Venerol. 68, 161-163.
25. Frank, S.B., and Cohen, H.J. (1964). The halo nevus. Arch. Dermatol. 89, 367-373.
26. Freeman, G.J., Long, A.J., Iwai, Y. et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034.
27. Gauthier, Y., Surleve-Bazeille, J.E., Gauthier, O., and Texier, L. (1975). Ultrastructure of halo nevi. J. Cutan. Pathol. 2, 71-81.
28. Gelfer, A., and Rivers, J.K. (2007). Long term follow-up of a patient with eruptive melanocytic nevi after Stevens-Johnson syndrome. Arch. Dermatol. 143, 1555-1557.
29. Girardi, M. (2007). Cutaneous perspectives on adaptive immunity. Clin. Rev. Allergy Immunol. 33, 4-14.
30. Gogas, H., Ioannovich, J., Dafni, U. et al. (2006). Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354, 709-718.
31. Hartmann, A., Bedenk, C., Keikavoussi, P., Becker, J.C., Hamm, H., and Bröcker, E. (2008). Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J. Dtsch. Dermatol. Ges. 6, 1053-1059.
32. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J.V., Steinman, R.M., and Nussenzweig, M.C. (2001). Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779.
33. Herschko, A.Y., and Rivera, J. (2010). Mast cell and T cell communication; amplification and control of adaptive immunity. Immunol. Lett. 182, 98-104.
34. Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T., and Tokura, Y. (2010). Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor of malignant melanoma. Cancer 116, 1757-1766.
35. Hodi, F.S. (2010). Overcoming immunological tolerance to melanoma: targeting CTLA-4. Asia Pac. J. Clin. Oncol. 6, S16-S23.
36. Hodi, F.S., O'Day, S.J., McDermott, D.F. et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
37. Igney, F.H., and Krammer, P.H. (2002). Immune escape of tumors: apoptotic resistance and tumor counterattack. J. Leukoc. Biol. 71, 907-920.
38. Igyarto, B.Z., and Kaplan, D.H. (2010). The evolving function of Langerhans cells in adaptive skin immunity. Immunol. Cell Biol. 88, 361-365.
39. Jacobs, J.F.M., Aarntzen, E.H.F., Sibelt, L.A.G. et al. (2009). Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol. Immunother. 58, 145-151.
40. Jensen, P., Hansen, S., Møller, B., Leivestad, T., Pfeffer, P., Geiran, O., Fauchald, P., and Simonsen, S. (1999). Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J. Am. Acad. Dermatol. 40, 177-186.
41. Kolm, I., Di Stefani, A., Hofmann-Wellenhof, R., Fink-Puches, R., Wolf, I.H., Richtig, E., Smolle, J., Kerl, H., Soyer, H.P., and Zalaudek, I. (2006). Dermoscopy patterns in halo nevi. Arch. Dermatol. 142, 1627-1632.
42. Kupper, T.S., and Fuhlbrigge, R.C. (2004). Immune surveillance in the skin: mechanisms and clinical consequences. Nature Rev. Immunol. 4, 211-222.
43. Lande, R., Gregorio, J., Facchinetti, V. et al. (2007). Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449, 564-569.
44. + T cells in melanoma-associated vitiligo. J. Invest. Dermatol. 117, 1464-1470.
45. Liu, J.B., Li, M., Yang, S., Gui, J.P., Wang, H.Y., Du, W.H., Zhao, X.Y., Ren, Y.Q., Zhu, Y.G., and Zhang, X.J. (2005). Clinical profiles of vitiligo in China: an analysis of 3742 patients. Clin. Exp. Dermatol. 30, 327-331.
46. Lu, Y., Zhu, W.Y., Tan, C., Yu, G.H., and Gu, J.X. (2002). Melanocytes are potential immunocompetent cells: evidence from recognition of immunological characteristics of cultured human melanocytes. Pigment Cell Res. 15, 454-460.
47. Mandalia, M.R., Skillman, J.M., Cook, M.G., and Powell, B.W. (2002). Halo naevus or malignant melanoma? A case report Br. J. Plast. Surg. 55, 512-513.
48. Meyerson, L.B. (1971). A peculiar papulosquamous eruption involving pigmented nevi. Arch. Dermatol. 103, 510-512.
49. Miller, L.S., and Modlin, R.L. (2007). Toll-like receptors in the skin. Semin. Immunopathol. 29, 15-26.
50. Moretti, S., Spallanzani, A., Pinzi, C., Prignano, F., and Fabbri, P. (2007). Fibrosis in regressing melanoma versus nonfibrosis in halo nevus upon melanocyte disappearance: could it be related to a different cytokine microenvironment? J. Cutan. Pathol. 34, 301-308.
51. + regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases. Br. J. Dermatol. 157, 531-539.
52. Musette, P., Bachelez, H., Flageul, B., Delarbre, C., Kourilsky, P., Dubertret, L., and Gachelin, G. (1999). Immune-mediated destruction of melanocytes in halo nevi is associated with the local expansion of a limited number of T cell clones. J. Immunol. 162, 1789-1794.
53. Nestle, F.O., and Nickoloff, B.J. (2007). Deepening our understanding of immune sentinels in the skin. J. Clin. Invest. 117, 2382-2385.
54. Ng., S.H., and Chave, T.A. (2006). Tumoral melanosis as a manifestation of a completely regressed primary melanoma with metastases. Br. J. Dermatol. 155, 627-644.
55. Nicholls, D.S., and Mason, G.H. (1988). Halo dermatitis around a melanocytic naevus: Meyerson's naevus. Br. J. Dermatol. 118, 125-129.
56. Nooijen, P.T., Westphal, J.R., Eggermont, A.M., Schalkwijk, C., Max, R., de Waal, R.M., and Ruiter, D.J. (1998). Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am. J. Pathol. 152, 679-682.
57. Oble, D.A., Loewe, R., Yu, P., and Mihm, M.C. Jr (2009). Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun. 9, 3.
58. Olàh, J., Gyulai, R., Korom, I., Varga, I., and Dobozy, A. (2003). Tumour regression predicts higher risk of sentinel node involvement in thin melanomas. Br. J. Dermatol. 149, 662-663.
59. Paravar, T., and Lee, D.J. (2010). Vitiligo in an urban academic setting. Int. J. Dermatol. 49, 39-43.
60. Paul, P., Rouas-Freiss, N., Khalil-Daher, I., Moreau, P., Riteau, B., Le Gal, F.A., Avril, M.F., Dausset, J., Guillet, J.G., and Carosella, E.D. (1998). HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA 95, 4510-4515.
61. Piaserico, S., Alaibac, M., Fortina, A.B., and Peserico, A. (2006). Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. J. Am. Acad. Dermatol. 54, 338-340.
62. Quaglino, P., Marenco, F., Osella-Abate, S., Cappello, N., Ortoncelli, M., Salomone, B., Fierro, M.T., Savoia, P., and Bernengo, M.G. (2010). Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann. Oncol. 21, 409-414.
63. Rados, J., Pastar, Z., Lipozencic, J., Ilic, I., and Stulhofer Buzina, D. (2009). Halo phenomenon with regression of acquired melanocytic nevi: a case report. Acta Dermatovenerol. Croat. 17, 139-143.
64. Ram, M., and Shoenfeld, Y. (2007). Harnessing autoimmunity (vitiligo) to treat melanoma - A myth or reality? Ann. N. Y. Acad. Sci. 1110, 410-425.
65. Ramón, R., Silvestre, J.F., Betloch, I., Banuls, J., Botella, R., and Navas, J. (2000). Progression of Meyerson's naevus to Sutton's naevus. Dermatology 200, 337-338.
66. Requena, C., Botella-Estrada, R., Traves, V., Nagore, E., Almenar, S., and Guillén, C. (2009). Problems in defining melanoma regression and prognostic implication. Actas Dermosifiliogr. 100, 759-766.
67. Rhodes, A.R. (1993). Neoplasms, benign neoplasias, hyperplasias, and dysplasias of melanocytes In Dermatology in General Medicine, T.B., Fitzpatrick, A.Z., Eisen, K., Wolff, I.M., Freedberg, and K.F., Austen, eds. 4th edn. (New York: McGraw-Hill), pp. 996-1077.
68. Romani, N., Clausen, B.E., and Stoitzner, P. (2010). Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol. Rev. 234, 120-141.
69. Rubegni, P., Nami, N., Risulo, M., Tataranno, D., and Fimiani, M. (2009). Melanoma with halo. Clin. Exp. Dermatol. 34, 749-750.
70. Saleh, F.H., Crotty, K.A., Hersey, P., and Menzies, S.W. (2001). Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. Int. J. Cancer 94, 551-557.
71. Serafini, P., Borrello, I., and Bronte, V. (2006). Myeloid suppressor cells in cancer recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16, 53-65.
72. Shaw, H.M., McCarthy, S.W., McCarthy, W.H., Thompson, J.F., and Milton, G.W. (1989). Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases. Histopathology 15, 257-265.
73. Slingluff, C.L., Vollmer, R.T., Reintgen, D.S., and Seigler, H.F. (1988). Lethal 'thin' malignant melanoma. Identifying patients at risk. Ann. Surg. 208, 150-161.
74. Sotiriadis, D., Lazaridou, E., Patsatsi, A., Kastanis, A., Trigoni, A., and Devliotou-Panagiotidou, D. (2006). Does halo nevus without halo exist? J. Eur. Acad. Dermatol. Venereol. 20, 1394-1396.
75. Swiecki, M., and Colonna, M. (2010). Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol. Rev. 234, 142-162.
76. Tefany, F.J., Barnetson, R.S., Halliday, G.M., McCarthy, S.W., and McCarthy, W.H. (1991). Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J. Invest. Dermatol. 97, 197-202.
77. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173, 1444-1453.
78. Wayte, D.M., and Helwig, E.B. (1968). Halo nevi. Cancer 22, 69-90.
79. Weishaupt, C., Munoz, K.N., Buzney, E., Kupper, T.S., and Fuhlbrigge, R.C. (2007). T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin. Cancer Res. 13, 2549-2556.
80. Woods, G.M., Malley, R.C., and Muller, H.K. (2005). The skin immune system and the challenge of tumour immunosurveillance. Eur. J. Dermatol. 15, 63-69.
81. Zattra, E., Fortina, A.B., Bordignon, M., Piaserico, S., and Alaibac, M. (2009). Immunosuppression and melanocyte proliferation. Melanoma Res. 19, 63-68.